Purpose To assess the long-term safety and effectiveness of the OptEase inferior vena cava (IVC) filter.
Introduction
Inferior vena cava (IVC) filters have shown to be effective in decreasing morbidity and mortality from pulmonary embolism (PE) in patients with deep venous thrombosis (DVT) who otherwise cannot receive standard medical therapy [1, 2] . However, concerns about their long-term safety have led to the introduction of retrievable or optional filters [2] [3] [4] . These filters are designed to be retrieved either within a specified time interval or at any time after their placement [5] . The retrievable filters are being increasingly used in all patient populations, specifically in young patients [6] . In addition, the prophylactic use of filters in patients affected by trauma has increased recently, more so after the availability of retrievable filters [6, 7] . However, in many series, the rate of retrieval of these filters has been\30% [8] . This potentially means that in a majority of patients who receive retrievable filters, the filter remains as a permanent device. The OptEase filter (Cordis Endovascular, Bridgewater, NJ) is a modification of the TrapEase filter (Cordis). It has a basket design similar to the TrapEase, but it has a hook at the lower end of the inferior cone for retrieval. The inferior prongs (or hooks) that attach to the caval wall have been removed, and the superior prongs have been redesigned to facilitate retrieval of the filter. Initial studies have documented the safety and effectiveness of this device in short term [9] [10] [11] . However, the long-term safety and effectiveness of this device is not known. Thus, the aim of our study was to assess the long-term safety and effectiveness of the OptEase IVC filter.
Materials and Methods
This retrospective study was approved by the Human Research Committee (Institutional Review Board) of our institution. The requirement to obtain informed consent from the subjects for this study was waived, although informed consent was obtained for the procedures themselves. The study was HIPAA-compliant.
Study Design
The interventional radiology database (HiIQ; ConexSys, Albion, RI) was interrogated to identify patients who had an OptEase IVC filter placed from 2002 to 2007. Clinical and imaging data were retrieved through electronic medical records and a picture archiving and communication system. Demographics, clinical presentation, underlying medical diseases, indications for filter placement, procedure-related data during placement and retrieval, filter-related complications, and follow-up clinical data were retrieved. When available, imaging studies (such as chest computed tomography [CT], abdominal CT, pelvic and lower-extremity CT, and Duplex ultrasound) were reviewed to evaluate asymptomatic filter-related problems and DVT occurring after filter placement. The data were entered in to a spreadsheet (MS Office Excel; Microsoft, Redmond, WA).The safety of the filter was assessed by calculating the incidence of symptomatic and asymptomatic filter-related complications (such as filter migration [i.e., migration of the filter [2 cm from its original location], filter penetration [i.e., filter legs protruding [3 mm outside the caval wall), filter tilt [i.e., [15°from the long axis of the IVC), filter fracture, and filter thrombosis) during placement, retrieval, and follow-up. The efficacy of the filter was assessed by calculating the incidence of PE during follow-up.
Patients and Clinical Presentation
During the 5-year period (2002) (2003) (2004) (2005) (2006) (2007) ) underwent imaging studies for evaluation of venous thromboembolism before filter placement, including CT pulmonary angiography (CTPA) and CT venography (n = 16), CT pulmonary angiography and venous ultrasound of the lower extremities (n = 11), CTPA (n = 11), venous ultrasound of the lower extremities (n = 15), CT venography (n = 3), and CTPA and MR venography (n = 1). Forty-four (44 of 57 [77%]) patients had venous thromboembolism on imaging studies. PE was diagnosed in 11, DVT in 23, and both DVT and PE in ten patients. Above-the-knee DVT was seen in 29, pelvic vein DVT in two, and below-the-knee DVT in two patients.
Indications for Filter Placement
The indications for filter placement included contraindication to anticoagulation in 31 ( Filter Deployment and Retrieval A standard protocol was followed for filter placement. Access to the IVC was obtained through the femoral or jugular vein or, rarely, through an upper-extremity vein. A 5F pigtail catheter (Cordis) was placed at the iliac vein confluence. Cavography was performed with 30 mL contrast material injected at a rate of 20 mL/s. The pigtail catheter was exchanged for the filter deployment sheath (the applicator), and the filter was deployed according to the manufacturer's instructions for use (IFU). A repeat cavogram was performed through the sheath. The sheath was removed, and hemostasis was achieved with manual compression.
Intravascular ultrasound (IVUS)-guided filter placement was performed if the patient could not be mobilized to the angiography suite due to the underlying medical condition. A right femoral vein was accessed, and 9F short sheath (Terumo, Somerset, NJ) was placed in the right common femoral vein. An IVUS catheter (Volcano, San Diego, CA) was advanced into the IVC. The renal veins were identified, and the intravascular length of the probe was measured. The filter deployment sheath was measured and marked accordingly. The filter sheath was advanced over the wire to the mark, and the filter was deployed per the IFU. A post-filter deployment IVUS was performed to assess the location of the filter in relation to the renal veins. The sheath and catheters were removed, and hemostasis was achieved through manual compression.
Lower-extremity venous Duplex study preceded any retrieval attempt. Retrieval of the filter was performed if there was no DVT or if previous DVT was stable or improving on anticoagulation. Right femoral venous access was obtained, and a 5F pigtail catheter (Cordis) was placed in the IVC. Cavography was performed. If there was no thrombus in the filter, the retrieval procedure was continued. The pigtail catheter was exchanged for a 10F-long sheath (Cook, Bloomington, IL). The filter hook was snared with a snare (GooseNeck snare; ev3, Plymouth, MN), and the filter was pulled into the sheath and removed. Postretrieval cavography was performed; the sheath was removed; and manual hemostasis was achieved.
Data Collection and Analysis
Procedure-related complications (e.g., hematoma, infection, injury to the vessels or organs) and technical success of filter deployment or retrieval (i.e., correct deployment of the filter at the intended location or successful retrieval of the filter) were calculated. The rate of access-site thrombosis was calculated. After filter placement, the incidence of clinical and CTPA-proven PE was calculated. Similarly, the incidence of symptomatic, recurrent, or new DVT and IVC occlusion was calculated. The incidence of incidentally detected asymptomatic DVT and IVC occlusion on abdominal CT scan and ultrasound studies was recorded. The incidence of symptomatic or asymptomatic filter migration, fracture, and tilt was recorded on follow-up imaging.
Results

Filter Implantation
Right common femoral venous access was used in 54 (54 of 71 [76.1%]) patients, whereas left femoral access was used in 13 ( patients, and gadolinium (Magnevist; Bayer) was used in one patient. Gadolinium was used becasue the patient had history of anaphylaxis to iodinated contrast material. Intravascular ultrasound was performed in six patients. Thrombus was seen in the infrarenal IVC in two patients. Duplicated cava was seen in one, circum-aortic left renal vein in one (who also had IVC thrombus), and extrinsic compression of the juxta-renal IVC in one patient. The filter was deployed in an infrarenal location in 64 (64 of 71 [90%]) patient and in the suprarenal location in 7 (7 of 71 [10%]) patients. In one patient with duplicated cava, two filters were placed, one in each cava. In one patient, the filter was malpositioned (filter placed upside down), and subsequent attempts to retrieve the filter were unsuccessful. A Tulip filter (Cook) was then placed above the malpositioned OptEase filter in a suprarenal location. There were no other complications during placement. The overall technical success was 98.6% (70 of 71).
Filter Retrieval
Filter retrieval was planned in 17 patients (17 of 71 [24%]) after a period of 15 ± 15 days (range 0-48). In three patients, the filter was not retrieved due to the presence of thrombus within the filter. Retrieval was attempted in 14 (14 of 71 [20%]) patients. The filter was successfully retrieved in 12 patients. In one patient, there was difficulty in snaring the hook of the filter. A snare-over-guidewire loop technique (or floss technique) [12] was used to retrieve the filter; however, the filter could not be successfully pulled into the sheath. The filter became crumpled and dislodged into the femoral vein. The filter was later surgically removed. In the other patient, the filter, which had a dwell time of 12 days, was adherent to the cava and could not be retrieved. Thus, the overall success in retrieving filters (on an intention-to-treat basis) was 12 of 17 (70.6%) patients. There was one major complication, as described, but there were no additional events.
Clinical Follow-Up
Clinical follow-up was available for all patients, and the data were retrieved from the electronic medical records. The mean clinical follow-up was 20 ± 21 months (range 1-78; median follow-up 12 months). During follow-up, 11 (11 of 71 [15.5%]) patients presented with symptoms of PE after a mean 31 ± 52 days. Of these 11 patients, eight underwent CTPA, and none of them had new PE. Thus, CT-proven symptomatic PE was 0%. Seven (7 of 71 [10%]) patients had new symptoms of DVT during followup. Six of the seven patients underwent ultrasound of the lower extremities, and the other patient underwent CT venography. One patient (1 of 7) showed new DVT on imaging. Thus overall, imaging-proven new DVT after filter placement was 1.4% (1 of 71). One patient (1.4%) had symptoms of caval occlusion (bilateral lower-extremity swelling and pain). This patient was treated by thrombolysis and filter removal. None with imaging follow-up had access-site thrombosis. After retrieval of the filter, patient follow-up ranged from 1 to 64 months (mean 24 ± 21). None had symptoms of recurrent PE. Three patients (3 of 14 [21%]) had symptoms of DVT, and ultrasound confirmed new DVT in all three patients. There was no access site DVT in these patients. 
Discussion
With the increasing use of IVC filters for prophylaxis against PE and preference for new designs aimed at retrieval, there has been a marked increase in the recent use of retrievable filters [5-8, 13, 14] . Early data demonstrated an acceptable safety profile of the OptEase filter [9] [10] [11] . However, a few in vitro studies and other in vivo shortterm data have suggested a thrombogenic potential of this filter [9, 15, 16] . This was later disputed by other investigators [17, 18] . Despite increasing awareness and attempts to retrieve these filters, the quoted retrieval rates in various studies have been approximately 30% [8, 13] . These retrievable filters have design modifications that enable them to be retrieved after implantation. However, the longterm effects of such modifications are not known given the fact that potentially 70% of these filters are left as permanent devices [8] .
Earlier reports on the OptEase filter were limited to short-term safety, efficacy, and retrieval data [9] [10] [11] . Our study provides clinical follow-up up to 78 months with a mean follow-up of 20 months. In our study, symptoms of post-filter PE occurred in 15.5% of patients, although no patient had PE documented on CTPA. Symptoms of new DVT after filter placement occurred in 10% of patients, although only one patient (1.4%) had imaging-proven new DVT. One patient had symptomatic cava occlusion. In addition, none had access-site thrombosis. These results support previous observations with regard to the efficacy of the filter [9] [10] [11] . The low rate of symptomatic caval occlusion supports a high safety profile of this filter, even over the long term. The low incidence of symptomatic access-site thrombosis may be related to the small size of the applicator used for implantation of this device. Similar to previous reports [8] , the filter retrieval rate was low in our study. The limited time window (23 days per the manufacturer) for successful removal of this filter after implantation is one of the reasons for this low rate of retrieval. Other filters, such as the Gunther Tulip (Cook), the Celect (Cook), and the G2 (Bard Peripheral, Temple, AZ), have extended time window B1 year for retrieval. Compared with the data from studies on other retrievable filters [19, 20] , the OptEase filter was associated with a low incidence of caval penetration, migration, and device fractures. Recent data on other retrievable filters are listed in Table 1 [9-11, 17, 19, 21-39] . Given the long-term morbidity and low rate of retrieval, IVC filters should be chosen carefully. In general, a retrievable filter with an extended time window for retrieval is preferable when filter retrieval is planned and successfully undertaken. When the filter retrieval rate is low, a filter with low incidence of major long-term complications should be considered.
The initial concerns of caval thrombosis as a result of the basket design of the OptEase filter are not supported by our observations. Similarly the largest study on the TrapEase filter, which has a similar design to the OptEase filter, also demonstrated a low incidence of symptomatic caval thrombosis [17] . However, presence of nonocclusive, asymptomatic trapped thrombi within the filter was observed in our study as well as previous studies [9, 17] . The role of the trapped thrombi within the filter on future occurrence of caval occlusion or PE requires further evaluation.
Inadvertent placement of the OptEase filter in an upsidedown configuration is a major safety concern because the filter hooks no longer provide protection against central migration and embolization to the heart and lungs. In one case where such complication occurred, we elected to place a suprarenal Tulip (Cook) filter above the OptEase filter. The main limitations of our study are the retrospective nature of the study, the small study population, and lack of the CT follow-up on all patients. Although it was a retrospective study, it provided long-term data on the safety and effectiveness of the filter. Because CT imaging in patients with vena cava filters is not currently recommended for routine follow-up, we reviewed available imaging studies to assess asymptomatic complications of the filter. The lack of CT follow-up in all patients would underestimate the incidence of asymptomatic complications. The retrieval of filters in our study was limited to a small fraction of patients, and in these patients the filter dwell time was short because the IFU recommends retrieval within a 23-day dwell period. As such, long-term retrievability of the filter cannot be assessed from our study.
Conclusion
In conclusion, the OptEase filter appears to have an acceptable long-term safety profile, although a prospective study with uniform clinical and imaging follow-up would be helpful to better define complications. The filter was effective against symptomatic PE. 
